Analysis of Para-aortic Lymphadenectomy Up to the Level of the Renal Vessels in Apparent Early-stage Ovarian Cancer

Overview

Journal J Gynecol Oncol

Specialties Gynecology & Obstetrics
Oncology

Date 2013 Jan 25

PMID 23346311

Citations 7

Authors

Suk-Joon Chang

Robert E Bristow

Hee-Sug Ryu

Affiliations

Soon will be listed here.

Abstract

Objective: The aim of this study was to evaluate the impact of para-aortic lymphadenectomy up to the renal vessels on the accurate staging in ovarian cancer patients presumed preoperatively to be confined to the ovary.

Methods: We retrospectively analyzed data on 124 patients with primary epithelial ovarian cancer who were preoperatively thought to have tumor confined to the ovary and underwent primary staging surgery. The distribution of lymph node metastasis and various risk factors for nodal involvement were investigated.

Results: SURGICAL STAGING YIELDED: 87 (70.2%) patients had International Federation of Gynecology and Obstetrics (FIGO) stage I disease and 37 (29.8%) patients had stage II-III disease: 4 IIA, 6 IIB, 9 IIC, 1 IIIA, and 17 IIIC. Eighty-six patients had pelvic lymphadenectomy only and 69 had pelvic and para-aortic lymphadenectomy. Lymph node metastases were found in 17 (24.6%) of 69 patients; 5 (7.2%) patients had lymph node metastasis in the pelvic lymph nodes only, 8 (11.6%) in the para-aortic lymph nodes only, and 4 (5.8%) in both pelvic and para-aortic lymph nodes. Six (8.7%) patients had lymph node metastasis in the para-aortic lymph node above the level of the inferior mesenteric artery. On multivariate analysis, grade 3 tumor (p=0.01) and positive cytology (p=0.03) were independent predictors for lymph node metastasis.

Conclusion: A substantial number of patients with apparently early ovarian cancer had upstaged disease. Of patients who underwent lymphadenectomy, some patients had lymph node metastasis above the level of the inferior mesenteric artery. Para-aortic lymphadenectomy up to the renal vessels may detect occult metastasis and be of help in tailoring appropriate adjuvant treatment as well as giving useful information about the prognosis.

Citing Articles

Prognostic significance and risk factors for pelvic and para-aortic lymph node metastasis in type I and type II ovarian cancer: a large population-based database analysis.

Yu H, Wang J, Wu B, Li J, Chen R J Ovarian Res. 2023; 16(1):28.

PMID: 36717897 PMC: 9885671. DOI: 10.1186/s13048-023-01102-8.

LncRNA MAFG-AS1 promotes the malignant phenotype of ovarian cancer by upregulating NFKB1-dependent IGF1.

Bai Y, Ren C, Wang B, Xue J, Li F, Liu J Cancer Gene Ther. 2021; 29(3-4):277-291.

PMID: 34035482 DOI: 10.1038/s41417-021-00306-8.

PLAG1 silencing promotes cell chemosensitivity in ovarian cancer via the IGF2 signaling pathway.

Huang W, Li B, Feng H Int J Mol Med. 2020; 45(3):703-714.

PMID: 31922228 PMC: 7015041. DOI: 10.3892/ijmm.2020.4459.

Prevalence and distribution pattern of nodal metastases in advanced ovarian cancer.

Bachmann C, Bachmann R, Kraemer B, Brucker S, Staebler A, Fend F Mol Clin Oncol. 2016; 5(4):483-487.

PMID: 27703680 PMC: 5038892. DOI: 10.3892/mco.2016.982.

Clinical epidemiology of epithelial ovarian cancer in the UK.

Doufekas K, Olaitan A Int J Womens Health. 2014; 6:537-45.

PMID: 24920935 PMC: 4043719. DOI: 10.2147/IJWH.S40894.

References

Le T, Adolph A, Krepart G, Lotocki R, Heywood M . The benefits of comprehensive surgical staging in the management of early-stage epithelial ovarian carcinoma. Gynecol Oncol. 2002; 85(2):351-5. DOI: 10.1006/gyno.2002.6636. View

Harter P, Gnauert K, Hils R, Lehmann T, Fisseler-Eckhoff A, Traut A . Pattern and clinical predictors of lymph node metastases in epithelial ovarian cancer. Int J Gynecol Cancer. 2007; 17(6):1238-44. DOI: 10.1111/j.1525-1438.2007.00931.x. View

Timmers P, Zwinderman K, Coens C, Vergote I, Trimbos J . Lymph node sampling and taking of blind biopsies are important elements of the surgical staging of early ovarian cancer. Int J Gynecol Cancer. 2011; 20(7):1142-7. DOI: 10.1111/igc.0b013e3181ef8e03. View

Morice P, Joulie F, Camatte S, Atallah D, Rouzier R, Pautier P . Lymph node involvement in epithelial ovarian cancer: analysis of 276 pelvic and paraaortic lymphadenectomies and surgical implications. J Am Coll Surg. 2003; 197(2):198-205. DOI: 10.1016/S1072-7515(03)00234-5. View

BURGHARDT E, Girardi F, Lahousen M, Tamussino K, Stettner H . Patterns of pelvic and paraaortic lymph node involvement in ovarian cancer. Gynecol Oncol. 1991; 40(2):103-6. DOI: 10.1016/0090-8258(91)90099-q. View

Grabowski J, Harter P, Buhrmann C, Lorenz D, Hils R, Kommoss S . Re-operation outcome in patients referred to a gynecologic oncology center with presumed ovarian cancer FIGO I-IIIA after sub-standard initial surgery. Surg Oncol. 2010; 21(1):31-5. DOI: 10.1016/j.suronc.2010.08.006. View

Nomura H, Tsuda H, Susumu N, Fujii T, Banno K, Kataoka F . Lymph node metastasis in grossly apparent stages I and II epithelial ovarian cancer. Int J Gynecol Cancer. 2010; 20(3):341-5. DOI: 10.1111/IGC.0b013e3181cf6271. View

Cress R, Bauer K, OMalley C, Kahn A, Schymura M, Wike J . Surgical staging of early stage epithelial ovarian cancer: results from the CDC-NPCR ovarian patterns of care study. Gynecol Oncol. 2011; 121(1):94-9. DOI: 10.1016/j.ygyno.2010.12.359. View

Suzuki M, Ohwada M, Yamada T, Kohno T, Sekiguchi I, Sato I . Lymph node metastasis in stage I epithelial ovarian cancer. Gynecol Oncol. 2000; 79(2):305-8. DOI: 10.1006/gyno.2000.5951. View

10.

Pereira A, Magrina J, Rey V, Cortes M, Magtibay P . Pelvic and aortic lymph node metastasis in epithelial ovarian cancer. Gynecol Oncol. 2007; 105(3):604-8. DOI: 10.1016/j.ygyno.2007.01.028. View

11.

Siegel R, Ward E, Brawley O, Jemal A . Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011; 61(4):212-36. DOI: 10.3322/caac.20121. View

12.

Rouzier R, Bergzoll C, Brun J, Dubernard G, Selle F, Uzan S . The role of lymph node resection in ovarian cancer: analysis of the Surveillance, Epidemiology, and End Results (SEER) database. BJOG. 2010; 117(12):1451-8. DOI: 10.1111/j.1471-0528.2010.02633.x. View

13.

Tsumura N, Sakuragi N, Hareyama H, SATOH C, Oikawa M, Yamada H . Distribution pattern and risk factors of pelvic and para-aortic lymph node metastasis in epithelial ovarian carcinoma. Int J Cancer. 1998; 79(5):526-30. DOI: 10.1002/(sici)1097-0215(19981023)79:5<526::aid-ijc14>3.0.co;2-#. View

14.

Goff B, Matthews B, Wynn M, Muntz H, Lishner D, Baldwin L . Ovarian cancer: patterns of surgical care across the United States. Gynecol Oncol. 2006; 103(2):383-90. DOI: 10.1016/j.ygyno.2006.08.010. View

15.

Young R, DECKER D, Wharton J, Piver M, Sindelar W, Edwards B . Staging laparotomy in early ovarian cancer. JAMA. 1983; 250(22):3072-6. View

16.

Sakuragi N, Yamada H, Oikawa M, Okuyama K, Fujino T, Sagawa T . Prognostic significance of lymph node metastasis and clear cell histology in ovarian carcinoma limited to the pelvis (pT1M0 and pT2M0). Gynecol Oncol. 2000; 79(2):251-5. DOI: 10.1006/gyno.2000.5933. View

17.

Takeshima N, Hirai Y, Umayahara K, Fujiwara K, Takizawa K, Hasumi K . Lymph node metastasis in ovarian cancer: difference between serous and non-serous primary tumors. Gynecol Oncol. 2005; 99(2):427-31. DOI: 10.1016/j.ygyno.2005.06.051. View

18.

Powless C, Aletti G, Bakkum-Gamez J, Cliby W . Risk factors for lymph node metastasis in apparent early-stage epithelial ovarian cancer: implications for surgical staging. Gynecol Oncol. 2011; 122(3):536-40. DOI: 10.1016/j.ygyno.2011.05.001. View

19.

Chan J, Munro E, Cheung M, Husain A, Teng N, Berek J . Association of lymphadenectomy and survival in stage I ovarian cancer patients. Obstet Gynecol. 2007; 109(1):12-9. DOI: 10.1097/01.AOG.0000249610.95885.ef. View

20.

Shih K, Chi D . Maximal cytoreductive effort in epithelial ovarian cancer surgery. J Gynecol Oncol. 2010; 21(2):75-80. PMC: 2895720. DOI: 10.3802/jgo.2010.21.2.75. View